NPPA and nephrotic syndrome: In a murine model of nephrotic syndrome, renal resistance to ANP is reversed by phosphodiesterase inhibitors, implying that this ANP resistance is mediated through enhanced cyclic GMP–phosphodiesterase activity (Valentin et al., 1992).